Recent developments in clinical trial designs for HIV vaccine research

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 4, 2015, Pages 1022-1029

  Richert, Laura ^a,b,c,d,e   Lhomme, Edouard ^a,b,c,d   Fagard, Catherine ^a,b,e   Lévy, Yves ^e,f,g,h   Chêne, Geneviéve ^a,b,c,e   Thiébaut, Rodolphe ^a,b,c,d,e  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d INRIA SISTM   (France)

^e Vaccine Research Institute (VRI)   (France)

^f INSERM U955   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

AIDS vaccines; Clinical trials; Epidemiologic research design; HIV; Prevention; Therapeutic use; Treatment outcome

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL DEVELOPMENT PLAN; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG RESEARCH; DRUG USE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MEN WHO HAVE SEX WITH MEN; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; REVIEW; STUDY DESIGN; TREATMENT OUTCOME; VACCINATION; VIRUS LOAD; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; HIV-1; HUMANS;

EID: 84945187233     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1011974     Document Type: Review

References (60)

1. Fauci AS, Folkers GK, Marston HD. Ending the Global HIV/AIDS Pandemic: The Critical Role of an HIV Vaccine. Clin Infect Dis 2014; 59 Suppl 2: S80-4; PMID:25151483; http://dx. doi. org/10. 1093/cid/ ciu420.
2. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361(23): 2209-20; PMID:19843557; http://dx. doi. org/10. 1056/ NEJMoa0908492.
3. Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203(7): 969-75; PMID:21402548; http://dx. doi. org/10. 1093/infdis/ jiq152.
4. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis 2012; 12(7): 531-7; PMID:22652344; http://dx. doi. org/10. 1016/ S1473-3099(12)70088-9.
5. Pantaleo G, Levy Y. Vaccine and immunotherapeutic interventions. Curr Opin HIV AIDS 2013; 8(3): 236- 42; PMID:23478912; http://dx. doi. org/10. 1097/ COH. 0b013e32835fd5cd.
6. Vanham G, Van Gulck E. Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology 2012; 9: 72; PMID:22958464; http://dx. doi. org/10. 1186/1742- 4690-9-72.
7. O'Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2012; 2(12): a007351; PMID:23209178; http://dx. doi. org/10. 1101/ cshperspect. a007351.
8. Koup RA, Graham BS, Douek DC. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 2011; 11 (1): 65-70; PMID:21164527; http://dx. doi. org/ 10. 1038/nri2890.
9. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366(14): 1275-86; PMID:22475592; http://dx. doi. org/10. 1056/NEJMoa1113425.
10. Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, et al. Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. J Virol 2014; 88(15): 8242-55; PMID:24829343; http://dx. doi. org/10. 1128/ JVI. 01164-14.
11. Gilbert PB. Some design issues in phase 2B vs phase 3 prevention trials for testing efficacy of products or concepts. Stat Med 2010; 29(10): 1061-71; PMID:20419758; http://dx. doi. org/10. 1002/ sim. 3676.
12. Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG. A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens. Stat Commun Infect Dis 2011; 3(1):1037; PMID:23181167.
13. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double- blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 2008; 372(9653): 1881-93; PMID:19012954; http://dx. doi. org/10. 1016/S0140- 6736(08)61591-3.
14. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 2011; 11(7): 507-15; PMID:21570355; http://dx. doi. org/ 10. 1016/S1473-3099(11)70098-6.
15. Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012; 54(11): 1615-7; PMID:22437237; http:// dx. doi. org/10. 1093/cid/cis238.
16. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG. A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 2007; 196(9): 1304-12; PMID:17922394; http://dx. doi. org/ 10. 1086/522428.
17. Gilbert PB, Qin L, Self SG. Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med 2008; 27(23): 4758-78; PMID:17979212; http://dx. doi. org/10. 1002/ sim. 3122.
18. Hua S, Lecuroux C, Saez-Cirion A, Pancino G, Girault I, Versmisse P, Boufassa F, Taulera O, Sinet M, Lambotte O, et al. Potential role for HIV-specific CD38-/ HLA-DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers. PloS one 2014; 9(7): e101920; PMID:25000587; http://dx. doi. org/ 10. 1371/journal. pone. 0101920.
19. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104(16): 6776-81; PMID:17428922; http://dx. doi. org/ 10. 1073/pnas. 0611244104.
20. Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle JH, Urrutia A, Scott- Algara D, Boufassa F, et al. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 2007; 81(24): 13904-15; PMID:17928341; http://dx. doi. org/10. 1128/ JVI. 01401-07.
21. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8(4): 431-40; PMID:2727467; http://dx. doi. org/10. 1002/ sim. 4780080407.
22. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482(7383): 89-93; PMID:22217938; http://dx. doi. org/10. 1038/ nature10766.
23. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15(3): 293-9; PMID:19219024; http://dx. doi. org/10. 1038/ nm. 1935.
24. Burgers WA, Manrique A, Masopust D, McKinnon LR, Reynolds MR, Rolland M, Blish C, Chege GK, Curran R, Fischer W, et al. Measurements of immune responses for establishing correlates of vaccine protection against HIV. AIDS Res Hum Retroviruses 2012; 28(7): 641-8; PMID:21861777; http://dx. doi. org/ 10. 1089/aid. 2011. 0239.
25. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2012; 9(4): 199-207; http://dx. doi. org/ 10. 1038/nrclinonc. 2011. 165.
26. Brown SR, Gregory WM, Twelves CJ, Buyse M, Collinson F, Parmar M, Seymour MT, Brown JM, et al. Designing phase II trials in cancer: a systematic review and guidance. Br J Cancer 2011; 105(2): 194-9; PMID:21712822; http://dx. doi. org/10. 1038/ bjc. 2011. 235.
27. Todd S. A 25-year review of sequential methodology in clinical studies. Stat Med 2007; 26(2): 237-52; PMID:17139691; http://dx. doi. org/10. 1002/ sim. 2763.
28. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman & Hall/CRC; 2000.
29. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med 2013; 369(22): 2083-92; PMID:24099601; http://dx. doi. org/10. 1056/NEJMoa1310566.
30. Commitee for medicinal products for human use (CHMP). Draft reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan. London, UK: European Medicines Agency; 2006. http://www. ema. europa. eu/docs/ en_GB/document_library/Scientific_guideline/2009/ 09/WC500003617. pdf, last accessed March 4, 2015.
31. Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials 2012; 13: 145; PMID:22917111; http:// dx. doi. org/10. 1186/1745-6215-13-145.
32. US. Department of Health and Human Services. Draft guidance for industry: adaptive design clinical trials for drugs and biologics. Silver Spring, Maryland: Food and Drug Administration (FDA); 2010. http://www. fda. gov/downloads/Drugs/Guidances/ucm201790. pdf, last accessed March 4, 2015.
33. Meurer WJ, Lewis RJ, Berry DA. Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA 2012; 307(22): 2377-8; PMID:22692168; http://dx. doi. org/10. 1001/jama. 2012. 4174.
34. van der Graaf R, Roes KC, van Delden JJ. Adaptive trials in clinical research: scientific and ethical issues to consider. JAMA 2012; 307(22): 2379-80; PMID:22692169; http://dx. doi. org/10. 1001/ jama. 2012. 6380.
35. Corey L, Nabel GJ, Dieffenbach C, Gilbert P, Haynes BF, Johnston M, Kublin J, Lane HC, Pantaleo G, Picker LJ, et al. HIV-1 vaccines and adaptive trial designs. Sci Transl Med 2011; 3(79): 79ps13; PMID:21508308; http://dx. doi. org/10. 1126/ scitranslmed. 3001863.
36. Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013; 368(6): 551-60; PMID:23388006; http:// dx. doi. org/10. 1056/NEJMra1204186.
37. Follmann D. Augmented designs to assess immune response in vaccine trials. Biometrics 2006; 62(4): 1161-9; PMID:17156291; http://dx. doi. org/10. 1111/ j. 1541-0420. 2006. 00569. x.
38. Excler JL, Rida W, Priddy F, Gilmour J, McDermott AB, Kamali A, Anzala O, Mutua G, Sanders EJ, Koff W, et al. AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses 2011; 27(6): 669-80; PMID:21043994; http://dx. doi. org/ 10. 1089/aid. 2010. 0206.
39. Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM. In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities. AIDS Res Hum Retroviruses 2013; 29(11): 1513-23; PMID:23597282; http://dx. doi. org/10. 1089/ aid. 2012. 0385.
40. Moodie Z, Janes H, Huang Y. New clinical trial designs for HIV vaccine evaluation. Curr Opin HIV AIDS 2013; 8(5): 437-42; PMID:23872613; http://dx. doi. org/10. 1097/COH. 0b013e328363d46a.
41. Eyal N, Kuritzkes DR. Challenges in clinical trial design for HIV-1 cure research. Lancet 2013; 382 (9903): 1464-5; PMID:24182529; http://dx. doi. org/ 10. 1016/S0140-6736(13)62040-1.
42. Moodie Z, Rossini AJ, Hudgens MG, Gilbert PB, Self SG, Russell ND. Statistical evaluation of HIV vaccines in early clinical trials. Contemp Clin Trials 2006; 27 (2): 147-60; PMID:16426900; http://dx. doi. org/ 10. 1016/j. cct. 2005. 11. 008.
43. Richert L, Doussau A, Lelievre JD, Arnold V, Rieux V, Bouakane A, Lévy Y, Chêne G, Thiébaut R; Vaccine Research Institute (VRI). Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design. Trials 2014; 15: 68; PMID:24571662; http://dx. doi. org/10. 1186/1745- 6215-15-68.
44. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL, McElrath MJ, De Rosa SC. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323(1): 39-54; PMID:17451739; http://dx. doi. org/10. 1016/j. jim. 2007. 03. 002.
45. Hudgens MG, Self SG, Chiu YL, Russell ND, Horton H, McElrath MJ. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J Immunol Methods 2004; 288(1-2): 19-34; PMID:15183082; http://dx. doi. org/10. 1016/j. jim. 2004. 01. 018.
46. Moodie Z, Huang Y, Gu L, Hural J, Self SG. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 2006; 315(1-2): 121-32; PMID:16959262; http://dx. doi. org/ 10. 1016/j. jim. 2006. 07. 015.
47. Alexander N, Fox A, Lien VT, Dong T, Lee LY, Hang Nle K, Mai le Q, Horby P. Defining ELISpot cut-offs from unreplicated test and control wells. J Immunol Methods 2013; 392(1-2): 57-62; PMID:23500146; http://dx. doi. org/10. 1016/j. jim. 2013. 02. 014.
48. Finak G, McDavid A, Chattopadhyay P, Dominguez M, De Rosa S, Roederer M, Gottardo R. Mixture models for single-cell assays with applications to vaccine studies. Biostatistics 2014; 15(1): 87-101; PMID:23887981; http://dx. doi. org/10. 1093/ biostatistics/kxt024.
49. Richert L, Thiebaut R. Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints? AIDS 2013; 27(8): 1362- 5; PMID:23759712; http://dx. doi. org/10. 1097/ QAD. 0b013e328360d52e.
50. Gilbert PB, Sato A, Sun X, Mehrotra DV. Efficient and robust method for comparing the immunogenicity of candidate vaccines in randomized clinical trials. Vaccine 2009; 27(3): 396-401; PMID:19022314; http:// dx. doi. org/10. 1016/j. vaccine. 2008. 10. 083.
51. Fong Y, Wakefield J, De Rosa S, Frahm N. A robust bayesian random effects model for nonlinear calibration problems. Biometrics 2012; 68(4): 1103-12; PMID:22551415; http://dx. doi. org/10. 1111/j. 1541- 0420. 2012. 01762. x.
52. Huang Y, Gilbert PB, Montefiori DC, Self SG. Simultaneous Evaluation of the Magnitude and Breadth of a Left and Right Censored Multivariate Response, with Application to HIV Vaccine Development. Stat Biopharm Res 2009; 1(1): 81-91; PMID:20072667; http://dx. doi. org/10. 1198/sbr. 2009. 0008.
53. De Gregorio E, Rappuoli R. From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol 2014; 14(7): 505-14; PMID:24925139; http://dx. doi. org/10. 1038/ nri3694.
54. Levy Y, Thiebaut R, Montes M, Lacabaratz C, Sloan L, King B, Pérusat S, Harrod C, Cobb A, Roberts LK, et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur J Immunol 2014; 44 (9):2802-10; PMID: 25042008; Epub ahead of print.
55. Saul A. Models of Phase 1 vaccine trials: optimization of trial design to minimize risks of multiple serious adverse events. Vaccine 2005; 23(23): 3068-75; PMID:15811654; http://dx. doi. org/10. 1016/j. vaccine. 2004. 10. 048.
56. Thiebaut R, Drylewicz J, Prague M, Lacabaratz C, Beq S, Jarne A, Croughs T, Sekaly RP, Lederman MM, Sereti I, et al. Quantifying and predicting the effect of exogenous interleukin-7 on CD4+ T cells in HIV-1 infection. PLoS Comput Biol 2014; 10(5): e1003630; PMID:24853554; http://dx. doi. org/10. 1371/journal. pcbi. 1003630.
57. Magni L, Raimondo DM, Bossi L, Man CD, De Nicolao G, Kovatchev B, Cobelli C. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007; 1(6): 804-12; PMID:19885152; http:// dx. doi. org/10. 1177/193229680700100603.
58. Roelofs E, Engelsman M, Rasch C, Persoon L, Qamhiyeh S, de Ruysscher D, Verhaegen F, Pijls-Johannesma M, Lambin P; ROCOCO Consortium. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 2012; 7(1): 165-76; PMID:22071782; http://dx. doi. org/10. 1097/ JTO. 0b013e31823529fc.
59. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194(12): 1661-71; PMID:17109337; http://dx. doi. org/10. 1086/508748.
60. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191(5): 654-65; PMID:15688278; http://dx. doi. org/10. 1086/428404.